Clinical Trials

3 articles

FIRSTAI-designed drug enters human trialsAI DESIGNPRECLINICALPHASE IIsomorphic LabsBuilt on AlphaFold + IsoDDE$3BLilly + Novartis partnerships
Clinical Trials

DeepMind CEO Confirms First AI-Designed Cancer Drug Entering Phase 1 Clinical Trials in 2026

Demis Hassabis confirmed that Isomorphic Labs' first AI-designed cancer drug will enter Phase 1 clinical trials in 2026, built on the AlphaFold-derived IsoDDE platform and backed by $3 billion in Lilly and Novartis partnerships.

·2 min
SERIES A$150M$850M valuationCo-founded by Eric SchmidtSpun out of UCL + King's College London$200M upfront to MeiraGTx for Parkinson's gene therapyDrug development + diagnostics + investment in one entity
Platform

Hologen, AI Biotech Co-Founded by Eric Schmidt, Raises $150M Series A at $850M Valuation

Hologen, co-founded by former Google CEO Eric Schmidt, is raising $150M at an $850M valuation, combining AI drug development with a $430M MeiraGTx gene therapy partnership for Parkinson's disease.

·2 min
INSILICO MEDICINE · JAN 2026$888MOncology deal with Servier$292M IPOHong Kong Stock Exchange · largest biotech IPO of 2025+45%day one15 cornerstone investors incl. Eli Lilly, Tencent, TemasekFirst AI-discovered drug (rentosertib) positive Phase 2a
Target Discovery

Insilico Medicine Strikes $888M Oncology Deal with Servier Days After Hong Kong IPO

Insilico Medicine announced an $888M oncology partnership with Servier days after raising $292M in the largest Hong Kong biotech IPO of 2025, with shares surging 45% on debut.

·2 min

Stay current

Weekly digest of AI drug discovery developments. No noise.